SCHEMBL1324936

SCHEMBL1324936

COC(=O)c1cnn2cc(Oc3cc(Cl)nc(N)n3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 4/20 0.44
RAB9A P51151 2/20 0.44
ADCY10 Q96PN6 2/20 0.41
PDE4B Q07343 1/20 0.40
NPC1 O15118 1/20 0.39
KDR P35968 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
PKM P14618 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
KDM4E B2RXH2 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
GPR119 Q8TDV5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303637 0.88 MEN1 (0.50) SMN1; SMN2KMT2AMEN1ALDH1A1RAB9A
SCHEMBL12124601 0.84 PDE4B (0.41) KMT2AALDH1A1RAB9APDE4BNPC1
SCHEMBL3484246 0.79 TDP1 (0.41) KMT2AALDH1A1RAB9APDE4BNPC1
SCHEMBL1325177 0.77 KDR (0.67) KDRGAA
SCHEMBL3616031 0.76 LCK (0.45) SMN1; SMN2KMT2AMEN1ALDH1A1RAB9A
SCHEMBL31383589 0.74 GAA (0.44) KMT2AMEN1ALDH1A1RAB9ANPC1
SCHEMBL30977391 0.74 EPHB3 (0.56) SMN1; SMN2KMT2AALDH1A1RAB9ANPC1
SCHEMBL3484724 0.71 MEN1 (0.52) SMN1; SMN2KMT2AMEN1ALDH1A1RAB9A
SCHEMBL4303613 0.71 KDR (0.37) ALDH1A1RAB9APDE4BNPC1KDR
SCHEMBL1325295 0.71 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AMEN1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058276-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2011-11-15 US disclosed
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases NOVARTIS AG (CH) 2009-01-29 US disclosed
EP-1996578-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2008009487-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases PHKG1, MAP3K20, CDK2 SMN1; SMN2 4023/4885KMT2A 887/4885MEN1 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.